Relmada Therapeutics (RLMD) Hisse Fiyat
Relmada Therapeutics Fiyat
Relmada Therapeutics şirketinin geliri, son 2 yılda yıllık %28,4 daralarak 5.129,00 USD seviyesine geriledi. Relmada Therapeutics için net marj, %-877,7 ile birkaç yıl önceki %-100,0 seviyesine göre geriledi. Relmada Therapeutics için 12 aylık konsensüs fiyat hedefi 11,00 USD; bu, hissenin bugünkü fiyatının yaklaşık %254,8 üzerinde bir seviyeye denk geliyor. 11 analistten 10 tanesi hisse için alım öneriyor — genel konsensüs: Al.
Relmada Therapeutics hisse senedi fiyatı
Bu verilere Eulerpool API üzerinden ulaşın
Ayda 100.000 ücretsiz istek · kredi kartı yok
Relmada Therapeutics iş modeli ve hisse analizi
Relmada Therapeutics hakkında sık sorulan sorular
Relmada Therapeutics Inc is a pharmaceutical company that focuses on developing and commercializing innovative therapies for various medical conditions. Their business model revolves around researching and developing novel drug candidates, acquiring intellectual property rights, conducting clinical trials, and seeking regulatory approvals for their innovative products. By leveraging their expertise in drug development, Relmada aims to address unmet medical needs and improve patients' quality of life. Through collaborations and strategic partnerships, the company strives to bring their innovative therapies to market and generate value for their stakeholders.
Relmada Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Relmada Therapeutics Inc in the market include companies such as Johnson & Johnson, Pfizer Inc, Novartis AG, and Eli Lilly and Company.
Relmada Therapeutics Inc is a pharmaceutical company specializing in the development and commercialization of novel therapies for various diseases. Founded in 2012, Relmada focuses on innovative solutions to address unmet medical needs and improve patients' lives. The company's research and development efforts primarily concentrate on central nervous system (CNS) disorders, including chronic pain, addiction, and rare diseases. Relmada Therapeutics Inc has successfully advanced several promising drug candidates through preclinical and clinical trials, demonstrating its commitment to delivering effective and safe treatments. With its dedication to scientific advancements, Relmada Therapeutics Inc is poised to make a significant impact in the evolving healthcare industry.
Relmada Therapeutics Inc has achieved several significant milestones. The company successfully completed Phase 2 trials for its lead product, d-Methadone, for the treatment of neuropathic pain. In addition, Relmada Therapeutics received Fast Track designation from the U.S. Food and Drug Administration (FDA) for d-Methadone, which expedites the development and review process. The company also completed a successful IPO, raising $65 million in gross proceeds. Relmada Therapeutics continues to advance its pipeline, focusing on innovative therapies for central nervous system (CNS) disorders. With its groundbreaking achievements, Relmada Therapeutics Inc has positioned itself as a key player in the pharmaceutical industry.
Relmada Therapeutics Inc primarily operates in the United States.
Relmada Therapeutics Inc represents values of innovation, commitment to patient wellbeing, and scientific excellence. The company is dedicated to developing novel therapies to address unmet medical needs. Relmada focuses on advancing research and developing cutting-edge treatments to improve patients' quality of life. Their corporate philosophy revolves around collaboration, ethical practices, and a patient-centric approach. Relmada Therapeutics Inc believes in fostering partnerships and leveraging scientific expertise to create transformative healthcare solutions. Through their dedication to innovation and commitment to advancing medical science, Relmada aims to make a meaningful impact in improving patient outcomes and addressing global healthcare challenges.
Analistler şu anda Relmada Therapeutics hissesi için ortalama 11,00 USD hedef fiyat belirliyor (medyan: 11,00 USD); bu, son fiyata göre +254,8 % anlamına gelir. Konsensüs 11 analist notuna dayanır.
11 analist şu anda Relmada Therapeutics hissesini değerlendiriyor: 10 al, 1 tut, 0 sat öneriyor. 2026 için analistler Relmada Therapeutics şirketinin 10,00 M USD gelir ve -0,28 USD hisse başına kâr üretmesini bekliyor.
Güncel döviz kuruyla Relmada Therapeutics hissesi 2,76 EUR (3,10 USD) seviyesindedir.
Relmada Therapeutics hissesi (RLMD) 3 borsada işlem görür, bunlar arasında: NASDAQ (RLMD), Frankfurt (4E2.F), München (4E2.MU).
Relmada Therapeutics Inc. is a biopharmaceutical company specializing in the development of novel therapeutics for central nervous system (CNS) disorders. The company is headquartered in New York City and offers a wide range of products and services tailored to the needs of patients and medical professionals. Relmada Therapeutics' business model is based on identifying, developing, and marketing innovative therapeutics for brain disorders and other psychiatric illnesses. The company holds a number of patents for developing biological therapeutics targeting various molecules within the human body. It has established an extensive network of partnerships with leading scientific and medical institutions to conduct a variety of clinical studies that help demonstrate the efficacy and safety of its products. Relmada Therapeutics' portfolio includes a range of novel therapeutics that can be used to treat a variety of psychiatric disorders. The company specializes in the development of preparations for the treatment of pain, depression, and addiction. Its flagship product is REL-1017, which targets the glutamatergic receptor and is currently in phase 3 clinical trials for the treatment of depression. In addition to its product pipeline, Relmada Therapeutics also offers a comprehensive range of services for medical professionals and patients. The company has a team of experienced clinical experts who assist customers in developing individualized treatment plans tailored to the specific needs of each patient. Relmada Therapeutics has also built a wide range of partnerships and alliances with key players in the pharmaceutical industry and healthcare. These partnerships enable the company to further expand its product development activities and improve the global marketing of its therapeutics. Overall, Relmada Therapeutics is an innovative biopharmaceutical company focused on improving the treatment of psychiatric disorders. Its comprehensive portfolio of products and services for medical professionals and patients, its experienced clinical experts, and its strong partnerships with other key players in the industry make it a significant player in the global market for psychiatric medications.
beklenen'nin Relmada Therapeutics hasılatı 10,00 M USD'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.
beklenen'nin Relmada Therapeutics karı -18,78 M USD'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.
Relmada Therapeutics'nin Fiyat/Kazanç (F/K) oranı şu anda -11,27'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların Relmada Therapeutics hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.
Relmada Therapeutics'nin Fiyat/Satış (F/S) oranı şu anda 21,16'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve Relmada Therapeutics hisse senedinin değerleme metriği olarak hizmet eder.
Relmada Therapeutics'nin Eulerpool Kalite Puanı 2/10'dur.
Relmada Therapeutics'nin ISIN'i US75955J4022'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.
Relmada Therapeutics'nin WKN'i A2PSZF'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.
Relmada Therapeutics'nin ticker'ı RLMD'dir. Ticker sembolü, Relmada Therapeutics hisseleri borsada işlem görmek için kullanılır.
Relmada Therapeutics Hissesi
Relmada Therapeutics Emsaller Grubu
Relmada Therapeutics Ticker
Relmada Therapeutics FIGI
Relmada Therapeutics'nin tüm temel göstergeleri ve derinlemesine analizi
Relmada Therapeutics hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve Relmada Therapeutics şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: